McIlrath & Eck’s Astria Therapeutics ATXS Stock Holding History

McIlrath & Eck’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-83	Closed	-$1.1K	–	900
2023 Q1	$1.1K	Buy	+83	New	+$1.12K	﹤0.01%	831

Other funds holding ATXS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

McIlrath & Eck's ATXS Position: Q2 2023 in Review

McIlrath & Eck sold out of Astria Therapeutics (ATXS) in Q2 2023, closing a stake of 83 shares — an estimated $1.1K sold.

McIlrath & Eck first reported a position in ATXS in Q1 2023 and held it in 1 quarter. The position peaked at $1.1K in Q1 2023. 76 funds tracked by Wall St. Rank hold ATXS as of Q2 2023.

McIlrath & Eck reported no remaining Astria Therapeutics position as of Q2 2023 after selling out during the quarter.
McIlrath & Eck sold 83 Astria Therapeutics shares in Q2 2023, an estimated $1.1K.
McIlrath & Eck first reported a position in Astria Therapeutics in Q1 2023 and held it in 1 quarter.
McIlrath & Eck's Astria Therapeutics position peaked at $1.1K in Q1 2023.
76 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2023.

Based on McIlrath & Eck's 13F filing for Q2 2023, filed 7 Aug 2023.